Marker Therapeutics Inc (MRKR) - Total Liabilities
Based on the latest financial reports, Marker Therapeutics Inc (MRKR) has total liabilities worth $3.64 Million USD as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See Marker Therapeutics Inc working capital to net assets to evaluate short-term liquidity relative to the company's equity base.
Marker Therapeutics Inc - Total Liabilities Trend (1999–2025)
This chart illustrates how Marker Therapeutics Inc's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see MRKR asset base.
Marker Therapeutics Inc Competitors by Total Liabilities
The table below lists competitors of Marker Therapeutics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Sphere 3D Corp
NASDAQ:ANY
|
USA | $1.74 Million |
|
Dunelm Group PLC
LSE:DNLM
|
UK | GBX622.70 Million |
|
Mexco Energy Corporation
NYSE MKT:MXC
|
USA | $1.30 Million |
|
Euro Kapital Yatirim Ortakligi AS
IS:EUKYO
|
Turkey | TL6.51 Million |
|
Climeon AB (publ)
ST:CLIME-B
|
Sweden | Skr33.82 Million |
|
Orgabio Holdings Bhd
KLSE:0252
|
Malaysia | RM37.80 Million |
|
Maniker F & G Co. Ltd
KQ:195500
|
Korea | ₩44.83 Billion |
|
ZECON Bhd
KLSE:7028
|
Malaysia | RM1.24 Billion |
Liability Composition Analysis (1999–2025)
This chart breaks down Marker Therapeutics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Marker Therapeutics Inc balance sheet quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.79 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.26 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.21 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Marker Therapeutics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Marker Therapeutics Inc (1999–2025)
The table below shows the annual total liabilities of Marker Therapeutics Inc from 1999 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $2.27 Million | -34.36% |
| 2024-12-31 | $3.46 Million | +12.67% |
| 2023-12-31 | $3.07 Million | -79.25% |
| 2022-12-31 | $14.82 Million | -38.63% |
| 2021-12-31 | $24.15 Million | +32.18% |
| 2020-12-31 | $18.27 Million | +703.77% |
| 2019-12-31 | $2.27 Million | -18.92% |
| 2018-12-31 | $2.80 Million | +84.17% |
| 2017-12-31 | $1.52 Million | -12.35% |
| 2016-12-31 | $1.74 Million | -93.80% |
| 2015-12-31 | $28.01 Million | +2143.90% |
| 2014-12-31 | $1.25 Million | -85.89% |
| 2013-12-31 | $8.85 Million | +53.27% |
| 2012-12-31 | $5.77 Million | +51.84% |
| 2011-12-31 | $3.80 Million | +12.15% |
| 2010-12-31 | $3.39 Million | +243.58% |
| 2009-12-31 | $986.35K | -67.94% |
| 2008-12-31 | $3.08 Million | +57.44% |
| 2007-12-31 | $1.95 Million | -38.06% |
| 2006-12-31 | $3.15 Million | +36.58% |
| 2005-12-31 | $2.31 Million | -8.65% |
| 2004-12-31 | $2.53 Million | +243.08% |
| 2003-12-31 | $736.95K | +149.31% |
| 2002-12-31 | $295.60K | +70.84% |
| 2001-12-31 | $173.03K | -74.66% |
| 2000-12-31 | $682.74K | +135.66% |
| 1999-12-31 | $289.71K | -- |
About Marker Therapeutics Inc
Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, develops and commercializes T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications in the United States. The company's multi antigen recognizing (MAR)-T cell therapy technology is based on the selective expansion of non-engineered tumor-specific T cells that recognize tumor-assoc… Read more